Condition: Β-thalassemia · Sponsor: Shenzhen Hemogen
This is a single-arm, open label, multi-center, single-dose Phase 1 clinical trial in subjects with transfusion dependent β-thalassaemia. The study aims to evaluate the safety and efficacy of autologous lentiviral-transduced CD34+ human hematopoietic stem cells (hHSCs) using the gene therapy product HGI-001.
This description comes directly from the study's public registry record.
Haigang Sun · 13823168465 · sunhaigang@genomics.cn
Linxia Qian · 18851685852 · qianlinxia@genomics.cn
Always discuss trial participation with your own doctor first.
| Guangxi Medical University First Affiliated Hospital | Guangxi, China | Recruiting |
| Shenzhen Children's Hospital | Shenzhen, China | Recruiting |
| Shenzhen University General Hospital | Shenzhen, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06655662